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Abstract
Background: The study explores differences and similarities in background and problem severity among those
seeking Opioid Substitution Treatment (OST), comparing those who primarily had misused "opiates", e.g. heroin,
morphine and opium, with those who primarily had misused other opioids.
Methods: Patients (n = 127) assessed for possible admittance in OST are compared based on the Addiction Severity
Index. Two groups based on primary type of opioid misused are compared (opiates vs. other opioids).
Results: In the global severity ratings there were no significant differences between the groups other than tautological
artefacts concerning heroin. There were few specific differences between the groups. The opiate group more often
had Hepatitis C and more often had legal problems related to financing their misuse. Injection of drugs was the main
method of administration in both groups, i.e. 90 % for mostly opiates vs. 75 % for mostly other opioids. A great
majority in both groups, 96 % vs. 91 %, had misused most other types of drugs. Both groups were found to have
severe problems in all areas investigated.
Conclusions: The study demonstrates great similarities in problem severity among those seeking OST, both those who
primarily had misused opiates and those who primarily had misused other opioids.
Keywords: Opiates, Opioids, Opioid-related disorders, Opioid Substitution Treatment
Background
Opioid dependence is a serious brain-related chronic
disease with a high risk of premature death [1–4].
Opioids can be used as painkillers and for other purposes
based on assessment by, and prescription of, a physician,
or they can be misused for getting high and other reasons
without prescription and against medical advice. Here the
term ‘opioid misuse’ always refers to use without prescrip-
tion or against medical advice. Opioid misuse occurs
worldwide. In 2012, the estimated prevalence in the age
group 15–64 years was between 26 and 36 million, of
which 50 % were misusing “opiates”, particularly heroin
[5]. There are currently a large number of opioid
drugs that are misused and can lead to dependence,
and the number of new synthetic drugs is rapidly in-
creasing [5, 6]. In 2012, it was reported that heroin
was partially being replaced by fentanyl and other
opioids in the European drug market [6]. In North
America and Oceania there is an increasing problem
with people becoming dependent on other kinds of
opioids than heroin [5, 7–11].
There is some confusion concerning the concepts of
opioids and opiates. ‘Opiates’ refer to the natural
derivatives of opium, while the main term ‘opioids’
includes both opiates and all other opioids with similar
effects [12–14]. All opioid substances activate the opioid
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receptors in the brain [15, 16]. Since the 1970s, drug
dependencies have been considered as diseases accord-
ing to the diagnostic systems ICD (International Classifi-
cation of Diseases) and DSM (Diagnostic and Statistical
Manual of Mental Disorders) [12, 13]. It should be clari-
fied that the diagnostic term for dependence on opioids
in both international diagnostic systems is opioid
dependence (F11.2 in the ICD-10 and 304.00 in the
DSM-IV), regardless of whether the substances misused
are heroin, morphine, opium or any other kind of opioid
(e.g. fentanyl, ketobemidone). As the negative effects of
substance use and dependence are considerable, effective
treatment is a matter of great concern. Opioid Substitu-
tion Treatment (OST) is a pharmacological treatment
with methadone or buprenorphine and is preferably
administered in combination with psychosocial treat-
ment and support interventions [17–21]. OST has been
extensively researched and has been shown to benefit
both individuals and society by reducing drug misuse and
the risk of premature death, and by promoting retention
in treatment, and social rehabilitation [3, 18, 19, 21–24].
OST was, in 2010, available in 77 countries [23]. The
WHO guidelines (2009) clearly addresses the treatment to
opioid dependency, based on the diagnosis according to
ICD-10 or DSM-IV, i.e. it does not depend on which type
of opioid substance misused [21].
Sweden is an exception to this. Sweden is traditionally
a very restrictive country when it comes to drug policy.
Although methadone maintenance treatment was intro-
duced in Sweden already in the 1966, as the first country
outside US, it was always regarded as an exception since
it did not comply with the political slogan “a drug-free”
society. The restrictive policies have gradually shifted
and OST is now regarded as a recommended treatment.
However concerns are still strong against “leakage” i.e.
prescribed drugs from the program sold at the illegal
market, and against having broad eligibility to the pro-
grams, and these concerns contributed to the
formulation of the Code of Statutes in a problematic
way. In March 2010, the Code of Statutes (SOSFS
2009:27(M)) was altered and patients dependent on
other opioids were no longer eligible for admittance to
OST. Only those dependent on “opiates” – defined in
the Code as three of the opium alkaloids: heroin, opium
and morphine – were admitted from that date. The
decision was not accompanied by any studies indicating
differences in needs for treatment and care between the
groups [25]. It was mentioned that there was a lack of
evidence concerning the effectiveness of OST for other
than those “dependent on opiates”. However, the SBU
(The Swedish Council on Health Technology Assessment)
concluded from a systematic review [26] in 2009 that OST
is an effective treatment regarding opioids, not distin-
guishing heroin, opium and morphine from other opioids.
In Sweden 2010, the average age of death, with presence
of heroin, morphine or methadone found at autopsy, was
36 years [27]. This problem was discussed by the Govern-
ment Task Force on Substance Misuse, which in 2011 re-
ported that about 10,500 persons in Sweden were
“addicted to opiates”. However, the term “opiates”, that
was used in a cited report, included all kinds of opioids as
well as natural derivatives (an example of the confusion
mentioned above). There is no epidemiological study that
specifies what kinds of opioids are used in Sweden. The
National Board of Health and Welfare (SoS) estimated in
February 2014 that about 3,700 people received OST at
about 90 OST units (personal communication with Ulf
Malmström, SoS). Thus, the majority of those dependent
on opioids are not admitted to OST. There is now a great
variety of poly drug use, administration patterns and spe-
cific mixtures of preparations, increasingly characterized
by a variety of opioids combined with other drugs [28].
Such patterns may complicate OST, and therefore have
clinical importance [28–32]. “Pure” heroin addicts are less
common, raising new demands for care and treatment
[5, 7, 28]. There are several studies comparing different
subgroups of misused opioids but none is comparable to
the Swedish categorization of opioids [9, 30–33]. Previous
research has mainly focused on heroin dependency.
Although there are studies on opioid dependency among
those using “prescription opioids” and “opioid-analgesics”,
those terms have different meanings in different publica-
tions – and in different countries [32–34]. The aim of this
study is to compare, based on type of opioid used, the
background and problem severity of groups of persons
who were assessed for OST.
The following three questions will be addressed: a)
Are there differences in the severity of drug problems or
in related problem areas (e.g. alcohol, health, social
situation)? b) If so, are the differences of clinical signifi-
cance? c) What is the situation specifically for those who
were categorized as opiate users in relation to those who
were categorized as users of other opioids?
Methods
This was a naturalistic study conducted at a Swedish
county hospital, and concerns persons assessed for OST
admittance in 2005–2011. In 2005, a manual-based OST
assessment was introduced at the clinic, supplemented
with ASI (Addiction Severity Index) interviews carried
out by referring municipal social boards. The OST
assessment was based on a thorough investigation of
documentation such as medical journals and police
registers, as well as a semi-structured interview. The
interview determined descriptive details of the social
situation, background, and medical and psychiatric
status (e.g. other illnesses) of the client. It also included
a comprehensive history of what kind of substances the
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person had used and misused and which of these
dominated. This included a breakdown of all types of
opiates and other opioids, as well as other substances
used, the duration and amount of doses of each drug,
the mixture of drug preparations, administration
patterns, experiences of overdoses and how these were
handled etc. The first author (BM) conducted all assess-
ments after 2005 following the same procedure.
The ASI is a valid and globally used structured inter-
view that estimates problem severity and need of help in
seven areas: medical status, employment and support
status, drug use, alcohol use, legal status, family and
social relationships and psychiatric status [35]. For these
seven areas, three different types of measurements are
used. First, there is the interviewer severity rating which
can range from 0 (= no problems/no help needed), to 9
(= life threatening problems/in urgent need of help).
The second is the self-assessment of needs, which
can range from 0 (= no problem/no help needed) to
4 (= very great problems/assistance definitely needed).
The third estimate is the number of days, within the
last 30, on which these problems were experienced,
varying from 0 to 30.
Before a patient is referred to OST, the ASI interview
with the person in question is usually carried out by the
referring municipal social worker. The social worker sends
the clinic the social assessment concerning the person,
including the ASI interview, along with a proposed treat-
ment plan for psychosocial interventions to supplement
the medical treatment. During the study we found that
different versions of the ASI had been used. Careful exam-
inations of the differences in wordings of specific items
were made, and 11 items with significant changes in
meaning were excluded from the analysis. Thus, the data
from the ASI interviews used here are comparable,
regardless of version.
The data on various problems presented in this article
are based on the ASI interviews, while the categorization
into the two groups, i.e. those categorized as having
primarily misused opiates vs. those categorized as having
primarily misused other opioids, is based on the OST
assessment. Eligibility for OST treatment– according to
Code of Statues for OST – must be validated by
documentation from e.g. hospital and police records
and/or drug tests, and thus should not be based only on
interview material.
The total number of patients considered for OST
during 2005-01-01 to 2011-06-30, was 153. Of these, 26
patients were transferred from another OST unit or
from a pain unit. These patients were excluded from the
present study since they were not assessed according to
clinical routines. Of the remaining 127 persons, 80
individuals (63 %) were categorized as having opiates as
their dominant drugs while 47 persons (37 %) were
categorized as having other opioids as their dominant
drugs of misuse. Although this paper concerns differ-
ences in problems and needs based on the ASI, it should
be noted that those categorized as users of other opioids
had all (100 %) lived in the Jönköping county or in rural
areas in nearby counties for a very long time, while 45 %
of those categorized as opiate users had either migrated
from another country, or from larger cities in other parts
of Sweden where heroin misuse had been established for
a longer time.
For 17 of the 127, it was found that the complete ASI
forms were not available and could not be obtained from
the municipal social services – only compiled reports
based on the original interviews were available. In order
to get complete data sets, these 17 individuals were
asked to participate in an ASI interview retrospectively,
focusing on the situation at the time they were actualized
for admittance to the OST program. Thus, the 127 ASI
interviews include 110 prospective and 17 retrospective
interviews (14 in the opiate group and three in the other
opioids group). The retrospective interviews were then
compared with the OST-investigation – including the
compiled reports of the original ASI interviews – and with
other hospital records, and found to be highly in
agreement. As a safeguard however, comparisons between
the opioid type groups were repeated without using the
retrospective interviews. That did not change any findings
though it weakened the statistical power due to there
being fewer cases.
Differences in mean values were tested for statistical
significance using a Student's T-test for two independent
groups. Kruskal-Wallis H-test was used when compari-
sons were made with ordinal and skewed interval scales.
When frequencies were compared, a Chi-2 test and
Fisher's exact test were used. The five per cent signifi-
cance level was applied.
Since the ASI data in this study enables a very large
number of group comparisons–in this case 249
variables–there is an obvious risk of mass significance.
That could result in a risk of getting 249 × 0.05 = 12
differences labelled as significant based solely on chance,
i.e. without real differences existing. This problem
justifies the use of a correction method. The Bonferroni
correction method multiplies p-values by the total num-
ber of comparisons, here possibly 249 comparisons. In
practice, it would be impossible to find significant values
with such a method. The Bonferroni method therefore
seems to be too restrictive and it might hide existing
group differences. This study therefore used a pragmatic
strategy involving two methods. First, the tables show
crude p-values, i.e. without applying any correction
method. Secondly, the Bonferroni-Holm correction
method was applied. Thus, the problem of mass signifi-
cance could be limited without hiding possible real
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differences. In addition to the use of p-values, 95 %
confidence intervals of differences in mean values and
boxplots of distributions of ordinal scaled indexes were
used in order to assess the degree of overlapping distri-
butions between the groups. Both these were explored
to detect possible differences of clinical relevance for
treatment and rehabilitation.
The study has been subjected to ethical review and
was approved by the Regional Ethical Review Board in
Linköping, 2011-06-15 (2011/214-31) and 2014-01-13
(2013/497-32).
Results
Table 1 presents the background characteristics and
demographic data of the two groups, i.e. those categorized
as having opiates vs. those having other opioids, as their
main types of drug.
The table indicates that no significant differences
between groups were detected. Both groups had used
the majority of opioids even if they had an “opioid of
choice” which – from the necessity of the code of
statutes – placed them in one of the groups.
Severity of problems in seven areas
Table 2 presents the severity of the seven problem areas,
based on the interviewers’ severity ratings, patients' self-
ratings of problem severity, and the number of days
within the last 30 that patients reported having had
these problems.
In five of the seven areas there were no significant dif-
ferences in any of the three global measures. Differences
were found in two areas: drug status and recent illegal
activities. All three measures detected a more severe
drug problem in the opiate group. However, those
differences in drug status did not hold when the
Bonferroni-Holm correction was applied. Another
difference concerned the number of days spent on illegal
activities for profit during the preceding 30 days. That
finding was also robust when applying the correction
method. These differences will be further explored in
the next section. The boxplot, however, showed that the
boxes as well as the arms totally overlapped between the
comparison groups. Hence, no differences of clinical
significance were indicated. Further comparisons on
Table 1 Comparison of background and demographics based
on ASI inter-views for two groups: those who dominantly used





n = 127 81 46
Gender, woman, % 14 20 .37 (a)
Age, m (sd) 36.5 (10.3) 35.4 (9.9) .49 (b)
In controlled environment
during the last 30 days, %
.20(a)
- No 58 70
- In drug-free residential or detox % 28 15
- Other 14 15
Number of days in controlled
environment last 30 days, m (sd)
6.19 (10.5) 4.91 (10.3) .52 (b)
Ethnicity, % .53 (a)
- Swedish 88 91
- Other 12 9
M (sd) = Mean (standard deviation). Significance tested by: a) Chi-2, b) T-test
for independent groups
Table 2 Comparison of global severity in seven problem areas,
based on the interviewers’ and self-assessed ASI severity ratings,
and number of days with the problem, for two groups of opioid
addicts, based on main type of opioid misused
Severity of problems n = 127 Opiates Other
opioids
Crude




Medical status 67/43 55.3 55.8 .946
Employment/support status 66/43 53.0 58.1 .395
Alcohol status 69/43 56.7 56.2 .941
Drug status 69/42 60.9 47.9 .034
Legal status 66/43 56.4 52.8 .527
Family/social relationships 67/42 53.3 57.8 .459




Medical status 76/46 60.8 62.7 .762
Employment/support status 75/45 59.2 62.7 .559
Alcohol status 78/46 63.2 60.0 .495
Drug status 77/46 66.3 54.8 .034
Legal status 76/46 62.3 60.1 .704
Family/social relationships 78/46 60.8 65.4 .471
Psychiatric status 77/45 57.5 68.3 .096
Number of problem days
in last 30, m (sd):
(b)
Medical status 77/46 14.1 (13.5) 15.3 (12.7) .232
Employment/support status 77/42 8.2 (13.0) 6.0 (11.4) .053
Alcohol status 79/45 3.4 (9.2) 2.2 (6.9) .095
Drug status 79/45 25.4 (10.0) 20.7 (12.8) .036
Recent illegal activities.
for profit
77/44 5.0 (10.0) 1.3 (5.0) .007**
Relationship problems 77/44 5.8 (10.9) 4.5 (9.0) .056
Psychiatric status 73/44 15.9 (13.2) 16.6 (13.6) .638
Significance tested by: a) Kruskal-Wallis H test, and b) T-test for two
independent groups
aOpiates group/Other opioids group. **Significant after Bonferroni-Holm correction
The average rankings (mean ranks)
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substance use problems are explored since differences
between the two groups concerning drug problems were
found in all three measures, the results of a further in-
vestigation of substance use problems on the level of
specific items are given in Table 3. The investigation
concerned what specific substances were used, indica-
tions of particularly hazardous use, e.g. injection and
overdose, duration of misuse, and whether misuse had
led to treatment.
Two of the significant differences concern heroin
(percentage using, and duration). Although these
differences were confirmed after Bonferroni-Holm
correction, they are tautological artefacts. They may
look like findings, but are just consequences of the
categorization, since heroin is the main opiate. Two
other findings concerned longer duration and earlier
age of onset of cannabis and amphetamine misuse in
the opiate group. In addition to these, there were
some findings that did not hold for the correction,
e.g. more persons injecting in the opiate group. How-
ever, it should be noticed that those who mainly
misused other opioids also had remarkably high rates
of injection (about 74 % compared to about 90 % for
the opiate group). More than 90 % of both groups
used multiple substances, and the two groups had
comparable numbers of overdoses. In addition, both
groups had multiple treatment episodes for various
substances.
Detailed comparisons concerning health and social situation
Table 2 above shows great similarities in severity in
all problem areas except drugs. Still, there might be
differences in specific problems that could be relevant
when deciding on the need for treatment and support.
The last table therefore shows comparisons between
the groups for health and social situation, in order to ex-
plore if there are variations that might justify differences
in treatment policies.
As shown in Table 4, a great majority in both
groups have chronic medical problems. There are no
significant differences between them neither regarding
chronic medical problems, nor in having the status of
disability pensioner due to such problems. However,
there is a difference in one specific medical problem,
since those who misused opiates more often suffer
from hepatitis C. As for psychiatric health, there are
no differences between the groups in specific prob-
lems such as anxiety, depression and suicidal
thoughts or acts. They are victims of emotional,
physical and sexual abuse to the same extent. The
groups are also similar in terms of social situation,
with very few cohabitating or being wage-earning em-
ployees. In Table 2, we find a difference concerning
the number of days during the last 30 spent on
illegal activities for profit. The opiate group has a
significantly higher rate of self-reported crime with
the aim of making money. This was expected based
on the much higher prices of heroin on the illicit
Table 3 Comparison of persons who had used opioids assessed
for OST, divided into two groups regarding substances used, for
how long, risky behaviour, and previous treatments, based on
ASI interviews
n = 127 Opiates Other
opioids
Crude
81/46a 81 46 p-values
Substances used, % (a)
Alcohol over threshold 80/45 78.8 84.4 .438
Heroin 80/45 96.3 64.4 <.001**
Methadone 78/45 78.2 66.7 .160
Other opiates/analgesics 80/46 97.5 100 .280
Medicines/pills (sedatives) 80/46 91.3 91.3 .992
Cocaine 78/45 71.8 51.1 .021
Amphetamines 80/45 92.5 91.3 .811
Cannabis 80/45 92.5 77.8 .018
Hallucinogens 77/44 72.7 56.8 .074
Inhalants 77/44 42.9 31.8 .231
Other 76/42 57.9 57.1 .937
Hazardous use
Multiple substances, % 75/43 94.7 90.7 .387
Injection, % 81/46 90.1 73.9 .016
Overdoses, m (sd) 77/44 5.0 (6.6) 3.1 (5.8) .219 (b)
Duration of use, years, m (sd) (b)
Alcohol over threshold 61/36 8.3 (9.6) 7.0 (8.3) .158
Heroin 72/23 8.6 (7.8) 1.7 (3.1) <.001**
Methadone 48/23 2.3 (5.0) 1.2 (2.5) .245
Other opiates/analgesics 72/39 8.9 (8.1) 10.7 (9.5) .164
Medicine/pills (sedatives) 68/37 9.0 (9.2) 9.0 (8.0) .245
Amphetamines 66/35 9.0 (9.3) 4.8 (4.8) .004**
Cannabis 66/33 11.5 (9.7) 6.3 (5.3) .001**
Hallucinogens 45/20 0.6 (1.1) 1.0 (2.6) .475
Inhalation 27/12 1.2 (2.2) 0.3 (0.6) .093
Others 33/20 0.9 (1.7) 2.9 (6.3) .188
Multiple substances 66/34 12.4 (8.9) 9.7 (8.5) .598
Injection 67/29 11.4 (9.4) 7.8 (8.9) .806
Treatments, m (sd)
Alcohol problems 80/45 9.3 (46.8) 5.1 (12.8 .226
Alcohol detox 73/43 4.1 (17.1) 2.5 (6.3) .159
Drug problems 80/40 14.7 (45.1) 9.7 (11.7) .426
Drug detox 73/42 6.4 (13.2) 6.3.(7.8) .785
Significance tested by a) Chi-2 if not otherwise stated, and b) Students T-test
for independent groups
aOpiates group/Other opioids group. ** Significant after Bonferroni-Holm correction
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drug market compared to other opioids, e.g. fentanyl.
However, there are no significant differences between
the groups regarding the number of times in life they
report having been charged with drug-related crimes,
crimes of property (i.e. robbery/theft), crimes of vio-
lence, driving drunk or doped, or other crimes, e.g.
vandalism. Both groups had been detained for drug
offenses. The only significant difference concerning
crimes in Table 4 is that the opiate group score
higher on having been apprehended for serious traffic
crimes. There are also no differences between the
groups concerning legal status, living with someone
who has problems with alcohol or drugs, the people
with whom they spend their leisure time, and how
satisfied they are with the situation (those variables
are not shown in the tables).
Discussion
All individuals in the study applied for OST when
they felt they had extensive problems with an opioid
dependence. The main finding of this study is that
there are great similarities between the groups con-
cerning severity of drug related problems as assessed
by ASI. This is consistent with the fact that both
groups, in everyday clinical practice, were perceived
to have extensive needs for care. The study does not
examine severity of opioid dependence, in terms of
diagnostic criteria (this will be focus in a coming art-
icle), nor does it explore all clinical differences be-
tween specific opioid substances. Instead, its focus is
on the relevance of the categorization in two groups
of opioids, i.e. opiates vs. other opioids as the bases
for OST eligibility. In most problem areas, severity
according to self- and interviewer ratings and num-
ber of days with a problem are similar when those
who used opiates and other opioids, respectively, are
compared. The main difference concerns drug prob-
lems, but a closer look at that problem area shows
that most differences are in fact tautological artefacts
concerning misuse of heroin, an opiate. Another dif-
ference concerning the number of days spent on il-
legal activities for profit is probably related to the
higher price of heroin. The current price of heroin
on the illicit market is between 50 and 160 Euros
per gram, depending on quality, which should be
compared to a common synthetic opioid such as
fentanyl which has a price varying between 15 and
30 Euros per patch (personal communication with
the police, June 2015).
Other findings are that a higher number of those
with mainly opiate use have also used cocaine and
cannabis, and they have a longer duration of cannabis
and amphetamine use compared with the “other opi-
oids group”. Only the two latter findings were con-
firmed after Bonferroni-Holm correction. These
findings, however, refer more to the participants’ drug
history than to the severity of their current problems.
Of special interest then are the indications of hazard-
ous use. The opiate group more often report that
they inject the drugs, but three out of four in the
Table 4 Comparison of health and social situation from ASI for
persons who misused opioids, divided into two groups, opiates
vs. other opioids
n = 127 Opiates Other
opioids
Crude
81/46a 81 46 p-values
Medical status %: (a)
Chronic medical problem 81/46 70.4 78.3 .334
Hepatitis C 81/44 66.7 38.6 .003**
Income from health insurance
for medical problems
81/45 19.8 20.0 .973
Sources of financial support
last 30 days %:
Health insurance 80/46 38.8 50.0 .219
Employment 80/46 17.5 8.7 .174
Psychiatric problems, previous
experienced %:
Serious depression 79/46 73.4 84.8 .142
Serious anxiety 78/46 79.5 87.0 .293
Serious suicide thoughts 77/43 61.0 74.1 .138
Suicide attempts 76/44 2.0 1.6 .150
Victim of emotional abuse 77/42 64.3 66.2 .831
Victim of physical abuse 76/43 55.3 58.1 .761
Victim of sexual abuse 76/42 23.7 21.4 .780
Treatment for psychiatric
problem in hospital, m (sd)
78/45 2.7 (6.2) 2.5 (6.3) .691(b)
Legal problems, m (sd):
Type of charges
(b)
- Drug-related crimes 77/38 6.7 (12.9) 3.4 (10.0) .550
- Crimes against property 76/39 7.7 (17.1) 4.1 (9.3) .136
- Crimes of violence 77/42 2.6 (7.1) 1.9 (3.7) .331
Apprehended for
- Driving drunk/doped 76/42 1.8 (3.9) 1.0 (1.9) .145
- Serious traffic crimes 76/41 3.6 (7.7) 0.7 (1.9) .002**
- Other crimes 77/39 2.4 (7.3) 1.4 (4.9) .239
Social status %:
Housing residence 81/46 .840 (a)
- Own housing contract 61 61
- Other housing 33 30
- Homeless 6 9
M (sd) = Mean (standard deviation). Significance tested by: a) Chi-2, b) T-test
for independent groups
aOpiates group/Other opioids group. ** Significant after Bonferroni-Holm correction
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other opioid group also report that they inject. Injec-
tion is an important indication of serious problems,
more important than the substance involved [36, 37].
In both groups, more than nine out of ten use mul-
tiple substances in combination the same day, both
groups had experienced multiple overdoses, and both
groups have been treated several times in detox as
well as for alcohol and drug problems. Both groups
have extensively used "other opiates and painkillers”
as well as “medicines/pills (sedatives)”, as labelled in
ASI. The type of opioid used may partly depend on
the local illicit market supply. And as mentioned in
the Methods section, the opiate users were more
often than opioid users migrants from areas where
heroin misuse was earlier established. The tendencies
however are similar to elsewhere, i.e. opioids that
may be prescribed as medicines are also more fre-
quent in irregular use [5–7].
Another explanation for the extended use of other
opioids may be that those who had not been admitted to
OST programs may have initiated an “OST on their
own”, i.e. used illicit buprenorphine or methadone as
self-medication to avoid continued adverse conse-
quences of using heroin and other opiates/opioids.
There is a difference between the groups concerning one
specific health problem, since opiate addicts more often
suffer from hepatitis C. This difference in percentages
infected, partly relates to the difference in injection rate.
But there may be more factors involved. One factor is
the onset time of intravenous administration, since early
onset time gives more possibilities to be infected, and
not just how often they now inject. Another factor is re-
lated to geography. In areas were Hep C is less spread,
the risk of being injected is less.
Looking at the total health picture, the similarities
are much greater, with all groups having severe
somatic as well as psychiatric health problems, with
additional severe problems in social situations. Thus,
the study shows that both groups in this study have
extensive problems, and that similarities between the
groups are much greater than differences. This is the
first study comparing the severities of problems
between groups of opioid users, based on the Swedish
categorization of opioid used, i.e. opiates vs other opi-
oids. Based on the results of ASI assessment, we find
no reasons for the categorization in the two groups
as a bases for eligibility to OST.
Methodological discussion
There is a need to discuss whether these findings are
credible, reliable and relevant. ASI interviews were used
in different versions from different years and authorities,
but since only items with the same or very similar word-
ings were used, this should not have affected the validity.
The ASI uses a categorization of drugs that is not
consistent with the categorization of opiates and other
opioids. Only heroin, methadone and Subutex are speci-
fied in the ASI questions. Other drugs based on the
same generic substances as Subutex (i.e. buprenorphine)
go into the drug category of “other opiates/painkillers”
along with morphine, opium and fentanyl. Those
variables from the ASI interview therefore have limited
validity for categorizing drugs into groups (opiates vs.
other opioids) relevant for the application of the statutes
(SOSFS 2009:27 (M)). Since our categorization instead is
based on the more accurately rendered OST assessment,
that above-mentioned problem does not affect the
present study. Data from the retrospective interviews
were compared with the information in the OST-
investigation and the hospital records to validate the
material. The only difference, which concerned num-
ber of days using in a month, can be interpreted as
lack of precise memory. That specific bias, however,
does not affect the findings of the study, since retro-
spective interviews were used with both groups.
Repeating comparisons between the drug type groups
without using the retrospective data did not change
the findings.
Implications
Since there are no previous studies comparing prob-
lem severity in opioid users between primary opiates
vs. other opiates used, this study may have some bearing
on legal policies. Similarities between the groups are strik-
ing, and the few differences found do not seem to provide
a rationale for different evaluations of the need for treat-
ment. Injection use seems to be more problematic among
the opiate users, but is also highly frequent among the
other group explored here. Hepatitis C is indeed a danger-
ous condition, but suicidal acts and using multiple
substances both constitute threats to the person’s life and
occur in both groups. These aspects may have an impact
on the kind of supplementary treatment needed.
Conclusions
Both groups assessed for OST– those who had used
opiates and those who had used other opioids – were
found to have extensive problem severity in all seven
ASI areas and should be considered as a heavy drug
use population with similar needs for treatment and
care. Since there are no previous studies conducted in a
natural setting, comparing problem severity in opioid
users between primary types of opioid used, this study
may have some bearing on the legal policies.
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